Rentschler Appoints Mark Caswell as Vice President, US Facility Site Head
Rentschler Biopharma has appointed Mark Caswell as Vice President and Site Head. He joined Rentschler in July 2022 and is managing all operations at the company’s US facilities in Milford, MA.
Caswell has more than 25 years of experience in the biopharmaceutical industry. Prior to joining Rentschler, he worked for over six years at Lonza Biologicals, most recently as Head of Operations at the Portsmouth, NH site. Before that, he worked for many years at Sanofi Genzyme (previously Genzyme) in positions of increasing responsibility.
“I am excited to welcome Mark Caswell to the Rentschler team. His many years of experience in the biopharma and CDMO space and diverse background in various areas of operations make him the perfect leader to run our US operations,” said Frank Mathias, CEO of Rentschler. “An important part of his responsibilities will be overseeing the completion of our state-of-the-art RBMC facility, the largest expansion in Rentschler Biopharma’s 150-year history.”
The responsibilities of Martin Kessler in his role as CEO of Rentschler Biopharma Inc. have been transferred to Caswell.
most read
BASF Sells Majority Stake in Coatings Business
BASF sells a majority stake in its coatings business to the investor Carlyle.
Ratcliffe: Chemical Industry in Europe at a Tipping Point
Ineos CEO Ineos calls on European politicians to save the chemical industry.
Dow to Shut Down Three Upstream European Assets
Building on the April 2025 announcement, Dow will take actions across its three operating segments to support European profitability, resulting in the closure of sites in Germany and the UK.
Merck Acquires Chromatography Business from JSR Life Sciences
Merck to acquire the chromatography business of JSR Life Sciences, a leading provider of CDMO services, preclinical and translational clinical research, and bioprocessing solutions.